The Biomedical Primate Research Centre (BPRC) is an independent, not-for-profit research institute aiming to improve human health by understanding and fighting life-threatening diseases. The use of non-human primates to do so does not only come with the responsibility to maximize animal welfare and research quality but also to develop alternatives. BPRC has an active and expanding program to develop alternatives following the principles of reduction, refinement and replacement.
BPRC is certified for responsible environmental policy (ISO 14001/2004) and is internationally recognized for its animal welfare policy (AAALAC).
Role of BPRC in VAC2VAC
BPRC participates by the development of physiochemical analytical methodology, by the development of immunochemical assays and we will utilize our library of bioassays that are based on mammalian cell lines to assess and standardize vaccine potency. This will all be done in the context of the development of alternative methods for animal tests that are currently in use in the approval process of traditional vaccines. The project fits seamless in the mission statement of BPRC in which the development of alternatives for animal research is one of the basics. With participation in VAC2VAC, BPRC establishes itself as a full partner in the development of alternatives for animal research.
Bart Faber (PhD, Department of Parasitology) is a biochemist that has been involved in protein subunit vaccine design, production and QA/QC for over 15 years. He will take part in the physiochemical and immunochemical assay development of protein vaccines.
Jeffrey Bajramovic (PhD, Alternatives Unit) is an immunologist and heads the Alternatives Unit. He has helped to successfully develop innovative in vitro technologies, designer cell lines and bioassays to replace, reduce and refine the use of non-human primates in biomedical research. These assays will be utilized to make innate immune fingerprints of different vaccines, vaccine batches and vaccine components.